Recent Finacing
Recent Raise
Hillhurst Biopharmaceuticals, a clinical-stage biopharma, uses the GLASS platform to make oral liquid therapeutic gases; lead HBI-002 (oral carbon monoxide) is in Phase 2a for sickle cell disease.
Focus Areas
Recent Investors
Funding round
Investor
See the team members at Hillhurst Biopharmaceuticals.
